1. The EasyMeasure Syringe Automated Syringe Dosing DeLorme, J.J., Hanson, E.E., Weisshaar, C.L., Wentland, A.L. Biomedical Engineering University of Wisconsin – Madison Advisor: Willis J. Tompkins, Ph.D.

2. Background/Motivation Many diabetes patients use syringes on a daily basis to inject insulin For diabetes patients with vision problems and neuromuscular disorders  It becomes difficult to read the volume of fluid on the syringe set the syringe’s plunger to the correct dosage Draw/inject the plunger at a steady rate (preventing air bubbles)

3. Current products Insulin pumps (Minimed) [1]  Costly (~$5,000)  Must be worn constantly and programmed Autoject2 ® -Owen Mumford [2]  Assists in injecting, not dosing Nordisk Novopen ® [3]  Requires some dexterity to set the dosage correctly  Uses only one type of insulin

4. The EasyMeasure Syringe Motor Keypad Digital Display Syringe

5. Cost Comparison Cost: Insurance Companies Cost: Patient Pump$5,000$0 Novopen ® (6 pens)$80+~$13 The EasyMeasure Syringe $100-300 Potentially $0 [1] [4] [5]

6. Market of Personal Care Products “The development of in-home medical technologies, substantial cost savings, and patients’ preference for care in the home have helped make this once small segment of the industry into one of the fastest growing in the U.S. economy.”  Career Guide to Industries, Bureau of Labor Statistics [6]

7. Market: >65 years In 2002, 12.4% of population was >65 [7]  12.4% of the population accounts for 40% of the annual healthcare costs [7] By 2020, this age group is expected to climb to 17% of the population [8] Diabetes and obesity on the rise [9] [10]

8. Market: Diabetes/Parkinson’s Patients Parkinson’s Disease: 1% of those >65 [12] Diabetes: 18.4% of those >65 [11] Over 65: 12.4% of US pop. [7]

9. Marketing towards Doctors & Insurance Companies Doctors are a major influence on patients’ purchase of products and services  Increases dosing accuracy  Strong alternative to insulin pumps  Easy-to-use keypad and easy-to-see digital display Insurance companies pay for >80% of products [13]  Cheaper than insulin pumps  Novopens, >$80, need refills and are more costly than The EasyMeasure Syringe  Savings over the long term

10. Introducing our Product to the Market FDA: Class I device [14]  Fewer restrictions than Class II/III devices  May be approved more quickly Present poster at a conference  Interface with doctors and professionals and compare device to existing products American Association of Diabetes Educators American Diabetes Association

11. Manufacture Easy to manufacture  Custom Parts Casing via injection molding Circuit  All other parts are available for purchase Potential manufacturability conflict  There are motors small enough for this application  However, smaller motors may have too little torque

12. Conclusions Beneficial to diabetes patients, especially with poor eyesight and/or poor motor skills Affordable and advantageous alternative to current products Competitive in the market Attractive to doctors, patients, and insurance companies

13. References [1] Medtronic. MiniMed. http://www.minimed.com/. 2004. [2] Owen Mumford. Autoject 2: Self injection made simpler…http://www.owenmumford.com /autoject2.html. 2004. [3] Novo Nordisk. NovoPen® 3 – An unsurpassed range. http://www.novonordisk.com/diabete s/public/insulinpens/novopen3/default.asp. 2004. [4] Midbon, Missy. Diabetes patient interview. 9/10/04. [5] Haist, Doug. Diabetes and Parkinson’s disease patient interview. 10/06/04. [6] Bureau of Labor Statistics. Industry Employment. Winter, 2000. [7] Healthcare Products & Supplies Industry Survey: Industry Trends. Standard & Poor’s Industry Surveys. Sept. 23, 2004. [8] US Census Bureau. Percent Distribution of the Population by Age: 1990 to 2050. http://www.census.gov/prod/1/pop/p25-1130/p251130b.pdf. 2005. [9] World Health Organization. Obesity and Overweight. http://www.who.int/hpr/NPH/docs/ gs_obesity.pdf. 2005. [10] International Union of Nutritional Sciences. http://www.iuns.org/features/obesity/tabfig.htm. 2005. [11] American Diabetes Association. National Diabetes Fact Sheet. http://www.diabetes.org /diabetes-statistics/national-diabetes-fact-sheet.jsp. 2005. [12] Center for Disease Control. National Center for Health Statistics: Data on Parkinson’s Disease. http://www.cdc.gov/nchs/data/factsheets/Parkinsons.pdf. 2005. [13] Puccinelli, John. Biomedical engineering Ph.D. student and diabetes patient interview. 2/4/05. [14] Food and Drug Administration. Device Classes. http://www.fda.gov/cdrh/devadvice/ 3132.html. 2005.